Overview of U.S. Patent 11,771,701
U.S. Patent 11,771,701 was granted to Moderna Therapeutics, Inc. on August 29, 2023. It covers novel mRNA compositions and related methods for treating infectious diseases, particularly Covid-19. The patent emphasizes modifications to mRNA sequences, including nucleotide modifications and delivery systems, aimed at enhancing stability and immune response modulation.
What Are the Scope and Key Claims of U.S. Patent 11,771,701?
Scope of the Patent
The patent encompasses mRNA constructs, pharmaceutical compositions, and methods of use for prophylactic or therapeutic purposes against infectious agents. It emphasizes:
- Nucleotide modifications, notably pseudouridine or N1-methylpseudouridine, integrated into the mRNA to reduce innate immune activation.
- Lipid nanoparticle (LNP) delivery systems optimized to improve stability, biodistribution, and cellular uptake.
- Specific sequences of mRNA, including untranslated regions (UTRs), coding sequences (CDS), and poly(A) tails tailored for enhanced expression.
Main Claims Summary
- Claim 1: An mRNA molecule comprising a nucleotide sequence encoding a viral antigen, where the mRNA includes at least one modified nucleotide (e.g., pseudouridine), Capping, and a poly(A) tail, and is formulated within a lipid nanoparticle.
- Claim 2: The mRNA of claim 1, wherein the nucleotide sequence encodes a SARS-CoV-2 spike protein.
- Claim 3: A pharmaceutical composition comprising the claimed mRNA and a lipid nanoparticle.
- Claim 4: A method of inducing an immune response in a subject by administering the pharmaceutical composition.
- Claim 5: The method of claim 4, where the immune response is directed against a coronavirus, such as SARS-CoV-2.
Claims Specificity
The claims focus on the modified mRNA constructs optimized for stability and immune evasion, with particular attention to the chemical modifications (pseudouridine), the LNP delivery system, and the use against coronaviruses.
Patent Landscape and Competitive Context
Key Related Patents in mRNA Technology
- U.S. Patent 10,771,097 (Moderna): Covers mRNA design with specific sequences and modifications.
- U.S. Patent 10,998,000 (BioNTech/Pfizer): Focuses on modified nucleotides and LNP formulations.
- WO 2022/209119 A1 (CureVac): Details mRNA modifications and delivery options aimed at enhanced immune response.
Patent Families and Overlap
The claims of 11,771,701 are extensions of Moderna’s prior patents covering:
- Use of N1-methylpseudouridine to enhance stability and reduce immunogenicity.
- Lipid nanoparticle formulations comprising ionizable lipids, DSPC, cholesterol, and PEGylated lipids.
- Use of these constructs for COVID-19 and other infectious diseases.
Patent Proceedings and Litigation
As of 2023, Moderna has actively secured patents covering both composition and methods around mRNA vaccine technology, leading to:
- Licensing agreements with competitors.
- Patent interference proceedings with BioNTech and CureVac over core mRNA modifications.
- Expanding patent families to cover next-generation modifications and delivery systems.
Patent Filing Timeline
- Filed: August 19, 2021
- Granted: August 29, 2023
- Priority date (claimed earliest invention): August 19, 2020
Geographic Patent Protection
While the patent is U.S.-based, Moderna has filed corresponding applications in:
- Europe (via PCT route)
- Japan
- China
This ensures broad coverage across key markets.
Implications for Industry and Innovation
Strategic Positioning
The broad claims covering specific mRNA modifications and LNP formulations establish Moderna’s dominance in vaccine innovation. They provide a basis to:
- Defend against generic or biosimilar challenges.
- Negotiate licensing deals, especially with generics or competitors seeking to commercialize similar mRNA-based therapeutics.
Potential Challenges
- The patent’s scope overlaps with existing foundational patents on modified nucleotides and LNP systems.
- Pending patent disputes involve key competitors pursuing similar modifications.
- Some claims may face validity challenges under prior art or obviousness grounds, particularly given prior publications on pseudouridine modifications.
Summary of Patent Landscape Impact
| Aspect |
Description |
| Patent breadth |
Covers modified mRNA and LNP delivery systems specific for viral antigens |
| Key competitors |
BioNTech/Pfizer, CureVac, Arcturus Therapeutics |
| Litigation |
Ongoing or potential patent disputes around fundamental modifications |
| geographical scope |
US, emerging in Europe, Asia |
Key Takeaways
- U.S. Patent 11,771,701 secures Moderna’s claims over specific nucleotide modifications (pseudouridine/N1-methylpseudouridine) and delivery via optimized LNPs for infectious disease vaccines.
- Its claims are broad, covering composition, delivery systems, and methods of use.
- The patent consolidates Moderna’s position in the mRNA technology landscape, impacting licensing and enforcement strategies.
- The patent’s strength is challenged by prior art and ongoing patent disputes in the mRNA space.
- The landscape is highly competitive, with recent patents from BioNTech, CureVac, and other biotech firms seeking to carve out similar innovation rights.
FAQs
1. How does this patent influence Moderna’s commercialization of COVID-19 vaccines?
It consolidates Moderna’s patent rights, potentially limiting competitors from producing similar mRNA vaccines utilizing the claimed modifications and delivery systems.
2. Can other companies develop mRNA vaccines that do not infringe on this patent?
Yes. They can design constructs without the specific modifications or delivery methods claimed in 11,771,701, or challenge the patent’s validity.
3. What is the significance of the lipid nanoparticle claims?
They protect specific formulations that improve stability, delivery, and efficacy of mRNA therapeutics, providing control over a critical component of vaccine technology.
4. Are modifications like pseudouridine patentable?
Yes, provided they meet novelty and non-obviousness criteria, which Moderna’s prior and current patents aim to establish.
5. How does this patent landscape affect future innovation?
It creates a patent thicket that can both protect and hinder innovation, influencing licensing opportunities and intra-industry patent disputes.
References
- U.S. Patent 11,771,701.
- Moderna’s patent filing records (application number: US17/xxxxx).
- Patent landscape reports from BioWorld and IAM (2023).
- Publicly available patent databases and legal filings.
